11646

協賛企業

Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients.

著者 Naya M , Tsukamoto T , Morita K , Katoh C , Furumoto T , Fujii S , Tamaki N , Tsutsui H
J Am Coll Cardiol.2007 Sep 18 ; 50(12):1144-9.
この記事をPubMed上で見るPubMedで表示

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

(74view , 0users)
OBJECTIVES: We aimed to compare the effects of the angiotensin II receptor blocker (ARB) olmesartan versus the calcium channel blocker (CCB) amlodipine on coronary endothelial dysfunction in patients with hypertension. BACKGROUND: Angiotensin II receptor blockers are thought to have greater beneficial effects than CCBs on coronary vasomotion by directly blocking action of angiotensin II. METHODS: Twenty-six patients with untreated essential hypertension were prospectively assigned to treatment with either olmesartan (27.7 +/- 12.4 mg/day, n = 13) or amlodipine (5.6 +/- 1.5 mg/day, n = 13) for 12 weeks. Changes of corrected myocardial blood flow (DeltaMBF) and coronary vascular resistance (DeltaCVR) from rest to cold pressor were measured by using 15O-water and positron emission tomography before and after treatment. Blood biomarkers including lipids, glucose, insulin, high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and superoxide dismutase (SOD) were also measured. RESULTS: Olmesartan and amlodipine reduced blood pressure (BP) to the same extent (-28.7 +/- 16.2 mm Hg vs. -26.7 +/- 10.8 mm Hg). In the olmesartan group, DeltaMBF tended to be greater (-0.15 +/- 0.19 ml/g/min vs. 0.03 +/- 0.17 ml/g/min, p = 0.09 by 2-way analysis of variance), and DeltaCVR was significantly decreased (7.9 +/- 23.5 mm Hg/[ml/g/min] vs. -16.6 +/- 18.0 mm Hg/[ml/g/min], p < 0.05) after treatment, whereas these parameters did not change in the amlodipine group (DeltaMBF: -0.15 +/- 0.12 ml/g/min vs. -0.12 +/- 0.20 ml/g/min; DeltaCVR: 6.5 +/- 18.2 mm Hg/[ml/g/min] vs. 4.8 +/- 23.4 mm Hg/[ml/g/min]). Serum SOD activity tended to increase (4.74 +/- 4.77 U/ml vs. 5.57 +/- 4.74 U/ml, p = 0.07 by 2-way analysis of variance) only in the olmesartan group. CONCLUSIONS: Olmesartan, but not amlodipine, improved endothelium-dependent coronary dilation in hypertensive patients independent of BP reduction. These beneficial effects on coronary vasomotion might be via an antioxidant property of ARBs.
PMID: 17868805 [PubMed - indexed for MEDLINE]
保存論文に追加 保存論文に追加

論文ランキング

週間人気論文ランキング - 閲覧数 (2010/07/24/ 09時更新)

Effects of bacterial toxins on endothelial tight junction in vitro: a mechanism-based investigation.

先週: 1位 ranksame 245view,2users 保存 要約を見る 要約

Prognostic impact of metastatic lymph node ratio on gastric cancer after curative distal gastrectomy.

先週: 3位 rankup 182view,0users 保存 要約を見る 要約

Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients.

先週: 8位 rankup 78view,11users 保存 要約を見る 要約

Personality disorders and biosocial trait theories: The argument for radical legal reform.

先週: 2位 rankdown 76view,2users 保存 要約を見る 要約

The differentiation of rat adipose-derived stem cells into OEC-like cells on collagen scaffolds by co-culturing with OECs.

先週: 9位 rankup 68view,11users 保存 要約を見る 要約

Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).

先週: 5位 rankdown 68view,0users 保存 要約を見る 要約

Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts.

先週: 7位 ranksame 64view,1users 保存 要約を見る 要約

A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study.

先週: 10位 rankup 34view,28users 保存 要約を見る 要約

Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.

先週: 6位 rankdown 34view,0users 保存 要約を見る 要約

An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).

先週: 4位 rankdown 30view,0users 保存 要約を見る 要約
※view数:週間 user数:合計